Cassava Sciences Shares Surged 27.5% Today, Here’s Why

Shares of Cassava Sciences Inc (NASDAQ: SAVA) today surged 27.5% premarket on news that Sanford Robertson a company director had bought 213,719 more shares for $1,491,759.

This was revealed via a Form 4 filing published by the US Securities and Exchange Commission (SEC) yesterday.

The company recently gapped higher after analysts upgraded its rating following the positive results of the Phase 2B clinical study of Sumifilam, its Alzheimer’s drug, where 98% of respondents showed improvements.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

This week has been a wild ride for Cassava Sciences investors as the company’s stocked has gapped significantly higher given that it was trading below the $4 level since May, and is now comfortably above the $8 price level representing a 100% gain.

Casava Sciences share price

Cassava Sciences shares today surged 27.5% to trade at a high of $9.04 after ending Thursday’s session trading at $7.09.

People who read this also read:

Casava sciences (SAVA) stock surges on Phase 2 study
Trade stocks with the highly-rated IG UK
Here are the 7 best shares to buy in 2020